Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc.

July 02, 2009 14:26 ET

Notice of Thallion Pharmaceuticals 2009 Second Quarter Conference Call

Second quarter financial results to be released on July 9, 2009

MONTREAL, QUEBEC--(Marketwire - July 2, 2009) - Thallion Pharmaceuticals Inc. (TSX:TLN) will release its 2009 second quarter financial results on Thursday, July 9, 2009 after 4:00 PM Eastern Time. The Company will subsequently hold a conference call on Thursday, July 9, 2009 at 4:30 PM Eastern Time hosted by Mr. Lloyd M. Segal, Chief Executive Officer and Mr. Michael Singer, Chief Financial Officer. A question and answer session will follow the corporate update.


DATE: July 9, 2009

TIME: 4:30 PM Eastern Time

DIAL IN NUMBER: 416-644-3419 or 1-800-731-5319

TAPED REPLAY: 416-640-1917 or 1-877-289-8525


A live audio webcast of the conference call will be available by visiting the Company's website at Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast.

About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX:TLN) is a biotechnology company developing pharmaceutical products in the areas of oncology and infectious disease. Thallion has three clinical programs at the Phase II stage of development. The two oncology product candidates include TLN-4601, a novel anti-cancer therapy targeting the RAS-MAPK pathway, and TLN-232, a peptide therapy targeting the M2 isoform of the metabolic enzyme pyruvate kinase (M2PK), with potential efficacy in multiple oncology indications. TLN-4601 and TLN-232 are currently recruiting patients in their respective multi-centre, Phase II, North American clinical trials. Thallion's third product candidate, Shigamabs®, is a dual antibody product for the treatment of Shigatoxin producing E. coli bacterial infections. Additional information about Thallion can be obtained at

Forward-Looking Statements

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the obtaining of court and other regulatory approvals and consents, the satisfaction of closing conditions, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

Contact Information